John J. Acton - Concepedia

Author

John J. Acton

Merck & Co., Inc., Rahway, NJ, USA (United States)

Also Known As

Acton, John J., J. Acton, J. J. ACTON, J. J. Acton, J. J. III ACTON, John Acton, John J. Acton, John J. III Acton, Joseph Acton

Publications

564

Citations

H-Index

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)

About

John J. Acton is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in pharmacology, medicine, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	300
2	Biochemistry	4	4	127
3	Natural Sciences	3	3	96
4	Engineering	1	1	15
5	Biomolecular Engineering	1	1	15

John J. Acton

Publications

474

Citations

H-Index

Page 1

	Year	Citations
Benzoyl 2-methyl indoles as selective PPARγ modulators John J. Acton, Regina M. Black, A. Brian Jones, Bioorganic & Medicinal Chemistry Letters Molecular PharmacologyFunctional SelectivityMedicineMechanism Of ActionChemical Biology	2004	130
Selective PPARγ modulators with improved pharmacological profiles Kun Liu, Regina M. Black, John J. Acton, Bioorganic & Medicinal Chemistry Letters Molecular PharmacologyG Protein-coupled ReceptorMedicineFunctional SelectivityPharmacological Agent	2005	62
(±)- Trans -2-(3-methoxy-5-methylsulfonyl-4-propoxyphenyl)-5-(3,4,5-trimethoxyphenyl)tetrahydrofuran (L-659,989), a novel, potent PAF receptor antagonist Mitree M. Ponpipom, San-Bao Hwang, Thomas W. Doebber, Biochemical and Biophysical Research Communications Molecular PharmacologyMedicinal ChemistryPharmaceutical ScienceBiochemistryMedicine	1988	58
Discovery of (2<i>R</i>)-2-(3-{3-[(4-Methoxyphenyl)carbonyl]-2-methyl-6-(trifluoromethoxy)-1<i>H</i>-indol-1-yl}phenoxy)butanoic Acid (MK-0533): A Novel Selective Peroxisome Proliferator-Activated Receptor γ Modulator for the Treatment of Type 2 Diabetes Mellitus with a Reduced Potential to Increase Plasma and Extracellular Fluid Volume John J. Acton, Taro E. Akiyama, Ching H. Chang, Journal of Medicinal Chemistry	2009	52
Structure-Guided Discovery of Aminoquinazolines as Brain-Penetrant and Selective LRRK2 Inhibitors Mitchell H. Keylor, Anmol Gulati, Solomon D. Kattar, Journal of Medicinal Chemistry	2021	40
Design of potent and selective GPR119 agonists for type II diabetes Jason W. Szewczyk, John J. Acton, Alan D. Adams, Bioorganic & Medicinal Chemistry Letters Diabetes ManagementBiochemistryFunctional SelectivityMedicineDiabetes	2010	31
Development, synthesis, and biological evaluation of (-)-trans-(2S,5S)-2-[3-[(2-oxopropyl)sulfonyl]-4-n-propoxy-5-(3-hydroxypropoxy)-phenyl]-5-(3,4,5-trimethoxyphenyl)tetrahydrofuran, a potent orally active platelet-activating factor (PAF) antagonist and its water-soluble prodrug phosphate ester N. N. Girotra, Tesfaye Biftu, Mitree M. Ponpipom, Journal of Medicinal Chemistry	1992	29
Synthesis and biological activity of MK 287 (L-680,573): a potent, specific and orally active paf receptor antagonist Soumya P. Sahoo, Donald W. Graham, John J. Acton, Bioorganic & Medicinal Chemistry Letters Biological ActivityBiochemistryFunctional SelectivityMedicineNatural Sciences	1991	19
Selective Protection and Relative Importance of the Carboxylic Acid Groups of Zaragozic Acid A for Squalene Synthase Inhibition Tesfaye Biftu, John J. Acton, Gregory D. Berger, Journal of Medicinal Chemistry Medicinal ChemistryBiosynthesisBioorganic ChemistryPharmaceutical ChemistryBiochemistry	1994	19
Discovery and Optimization of Potent, Selective, and Brain-Penetrant 1-Heteroaryl-1 <i>H</i> -Indazole LRRK2 Kinase Inhibitors for the Treatment of Parkinson’s Disease David A. Candito, Vladimir Simov, Anmol Gulati, Journal of Medicinal Chemistry	2022	19

Page 1